NCPC: Southern Company Obtains Drug Registration Certificate

NCPC announced that its wholly-owned subsidiary, Southern Company, has received the drug registration certificate for injectable Imipenem and Cilastatin Sodium issued by the National Medical Products Administration. This drug is a compound formulation consisting of Imipenem and Cilastatin Sodium, suitable for various infections caused by sensitive bacteria. Southern Company applied for and obtained the drug registration acceptance number in June 2024 and received the drug registration certificate in September 2025. As of now, the cumulative R&D investment is 5.2243 million yuan. The domestic market has shown good growth in recent years, with sales reaching 2.3 billion yuan in 2024 and a sales volume of approximately 20 million units